CA Patent

CA2551409C — Prostaglandin nitrooxyderivatives

Assigned to Nicox SA · Expires 2011-02-22 · 15y expired

What this patent protects

Prostaglandin nitrooxyderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension. A compound of general formula (I) is described wherein R is the prostaglandin residue of…

USPTO Abstract

Prostaglandin nitrooxyderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension. A compound of general formula (I) is described wherein R is the prostaglandin residue of formula (II): (I) (see formula II)

Drugs covered by this patent

Patent Metadata

Patent number
CA2551409C
Jurisdiction
CA
Classification
—
Expires
2011-02-22
Drug substance claim
No
Drug product claim
No
Assignee
Nicox SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.